WHAT IS CLAIMED:

1. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable region, said light chain variable region comprising:

    a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO: 59, a CDRL2 amino acid sequence of SEQ ID NO: 67 and a CDRL3 amino acid sequence of SEQ ID NO: 75; or

    a CDRL1 amino acid sequence of SEQ ID NO: 62, a CDRL2 amino acid sequence SEQ ID NO: 68 and a CDRL3 amino acid sequence of SEQ ID NO: 75.

2. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region, said heavy chain variable region comprising:

    a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO: 43, a CDRH2 amino acid sequence of SEQ ID NO: 46, and a CDRH3 amino acid sequence of SEQ ID NO: 58; or

    a CDRH1 amino acid sequence of SEQ ID NO: 44, a CDRH2 amino acid sequence of SEQ ID NO: 47, and a CDRH3 amino acid sequence of SEQ ID NO: 58.

3. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a CDRL1 amino acid sequence of SEQ ID NO: 62,

a CDRL2 amino acid sequence of SEQ ID NO: 68,and

a CDRL3 amino acid sequence of SEQ ID NO: 75; or

a CDRL1 amino acid sequence of SEQ ID NO: 59,

a CDRL2 amino acid sequence of SEQ ID NO: 67, and

a CDRL3 amino acid sequence of SEQ ID NO: 75; and said heavy chain variable region comprising:

a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs: 44 and 161,

a CDRH2 amino acid sequence of SEQ ID NO: 47, and

a CDRH3 amino acid sequence of SEQ ID NO: 58; or

a CDRH1 amino acid sequence of SEQ ID NOs: 43,

a CDRH2 amino acid sequence of SEQ ID NO: 46, and

a CDRH3 amino acid sequence of SEQ ID NO: 58.

4. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable amino acid sequence and a heavy chain variable amino acid sequence, wherein the light chain variable amino acid sequence comprises SEQ ID NO: 143 and the heavy chain variable amino acid sequence comprises SEQ ID NO: 133.

5. The isolated antibody of claim 4, further comprising an IgG4 heavy chain constant region and an IgG4 light chain constant region.

6. The isolated antibody of claim 4, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 159 and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 160.

7. An isolated human CD27-neutralizing antibody or antigen-binding fragment thereof, said antibody or antigen-binding fragment binding to an epitope bound by the antibody of claim 4 as determined by binding to immobilized CD27 extracellular domain.
8. The isolated antibody of claim 4, wherein said antibody binds to human CD27 with a $\mathbf{K_D}$ of 1 x 10^{-7} M or less as determined by surface plasmon resonance.
9. An isolated nucleic acid molecule, selected from the group consisting of (i) a nucleotide sequence encoding the antibody or antigen binding portion of claim 4, (ii) a nucleotide sequence encoding the antibody of claim 6 or (iii) a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO: 143 and/or a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO: 133.
10. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 9.
11. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 10.
12. The host cell according to claim 11, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.
13. A method for producing a CD27 antibody, comprising incorporating the nucleic acid molecule of claim 9 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.
14. A CD27 antibody or antigen-binding fragment thereof of any one of claims 1 to 8 for use in inhibiting naïve T-cell proliferation, wherein the CD27 antibody or antigen-binding fragment thereof inhibits the activation of CD27 on human T-cells in the presence of human CD70 protein or a portion of human CD70 protein.
15. An article of manufacture comprising a pharmaceutically acceptable formulation comprising the antibody of claim 4.
16. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable amino acid sequence selected from the group

consisting of SEQ ID NOs: 137 and 143.

17. The isolated antibody or antigen-binding fragment thereof of claim 17, further comprising a heavy chain variable amino acid sequence selected from the group consisting of SEQ ID NOs: 128 and 133.

18. An isolated human CD27 antibody or antigen-binding fragment thereof, comprising a heavy chain variable amino acid sequence selected from the group consisting of SEQ ID NOs: 128and 133.